Coherus BioSciences and FreightCar America Face Pivotal Q4 Earnings Tests
Coherus BioSciences is navigating a high-stakes pivot toward its innovative oncology portfolio, while FreightCar America seeks to capitalize on a robust railcar replacement cycle. Both companies face critical Q4 2025 earnings calls that will define their 2026 growth trajectories and capital allocation strategies.